It remains to be determined whether an increasing level of CD133+ tumor initiating cells, presumably in part due to hypomethylation of the CD133 promoter region contributes to the pathobiology of the advanced stage tumor or is an indirect consequence of disease progression. The gene discussed is PROM1; the disease is neoplasm.